BRONCHODILATORS → LONG-ACTING BETA-2 AGONIST (LABA) → Serevent®

Serevent®

BRONCHODILATORS

LONG-ACTING BETA-2 AGONIST (LABA)

  • Class

    • Long-acting beta-2 agonist (LABA)

  • Active ingredient

    • Salmeterol (as the xinafoate salt)

  • Device

  • Age

    • 4 +

  • Typical use

    • Asthma
      in addition to an ICS when uncontrolled

    Asthma management principles

    • COPD
      initial treatment or in addition to a LAMA when uncontrolled

    COPD management principles

  • Marketed strength

    • 50 mcg

  • Number of doses

    • 60 doses

  • Dose indicator

    • Yes | Numerical

  • Usual adult dosage

    • 1 inh BID

  • Usual pediatric dosage

    • Not recommended as a standalone in pediatrics

  • Required inspiratory flow

    • > 30 - 60 L/min
      Medium-low internal resistance (R2)

    Inspiratory flows

  • Public coverage

    • AB – MN – QC | Open/Regular Benefit
      BC – NB – NIHB – NL – NS – ON – PEI – SK – YT | Restricted Benefit with criteria

    Provincial coverage criteria

  • Advantages

    • Precise dose counter

  • Disadvantages

    • Risk of misuse without an ICS in asthma (increased mortality)
    Side effects

Product monograph

Download

Oxeze®

Turbuhaler®

Search for other inhalers

Explore the full list